Prospects of using bacteriophage M13 as a vector vaccine against Newcastle disease

Abstract

Newcastle disease of birds remains a major problem in veterinary medicine and the poultry industry in general. The emergence of new strains of Newcastle disease virus (NDV) also creates new needs for the development of vaccines containing more homologous antigens to new strains. Since vaccination through a watering system or by spray vaccination is more technologically advanced than injection vaccination, we proposed to use bacteriophages as a means of antigen delivery. To do this, we have carried out search for bacteriophages suitable for delivering a recombinant antigen (as part of a fusion protein with a bacteriophage capsid protein) through mucous barriers. Experiments on laboratory animals made it possible to determine the longest circulation in the circulatory system of bacteriophages M13 and PA136. To develop a technology for creating recombinant vaccines against Newcastle disease based on bacteriophage M13, we were studied the domain structure of the NDV F protein, searched for B dependent epitopes, and developed primer systems for cloning a fragment of the NDV F protein in the H1 domains - 1a of the F protein (33-55 aa) in position 4649 to 4715 b.p. and gene VIII of bacteriophage M13. This construct was cloned into the pET32b expression vector. The production of recombinant protein simultaneously with the replication of bacteriophage M13 and the packaging of this protein into the bacteriophage capsid is possible in the E. coli F+ system which potentially allows cloning variable, strain-specific regions of the NDV F protein directly from pathological material and using such a recombinant vaccine to priming of classical, highly immunogenic vaccines.